 |
|
|
|
 |
|
|
| Article 1 to 2 out of 2 concerning Nabi Biopharmaceuticals
|
-
Nabi Biopharmaceuticals Creates Pharmaceuticals Business Unit
(23 Jul 2007)
Nabi Biopharmaceuticals has created the second of its two planned strategic business units (SBU), Nabi Pharmaceuticals. Nabi Pharmaceuticals is responsible for the NicVAX(R) (Nicotine Conjugate Vaccine) and StaphVAX(R) (Staphylococcus aureus ...
-
Anti-smoking Vaccine in Second Phase
(21 Jul 2005)
Nabi Biopharmaceuticals Announces Completion of NicVAX(TM) Phase II Clinical Trial Enrollment
BRAY, Ireland. Nabi Biopharmaceuticals (Nasdaq: NABI) announced today that it has completed enrollment for its European-based NicVAX(TM) (Nicotine Conjugate Vaccine) Phase II dose-ranging study in smokers. NicVAX is a novel, innovative, and ...
|
|
|
|
|
Top
